Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)
NCT00129831
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
6
Enrollment
INDUSTRY
Sponsor class
Conditions
COPD
Interventions
DRUG:
QAB149
Sponsor
Novartis